Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux

M Marcil1, A Brooks-Wilson, S M Clee

  • 1Xenon Bioresearch Inc, NRC Innovation Centre, Vancouver, British Columbia, Canada.

Lancet (London, England)
|October 26, 1999
PubMed

Insights

Mutations in the ATP-binding-cassette (ABC1) gene cause familial high-density lipoprotein (HDL) deficiency by impairing cellular cholesterol efflux. This highlights ABC1 modulation as a potential strategy for increasing HDL levels.

Area of Science:

  • Genetics and Molecular Biology
  • Cardiovascular Research
  • Metabolic Disorders

Background:

  • Low high-density lipoprotein (HDL) cholesterol is common in premature atherosclerosis.
  • Tangier disease, a severe HDL deficiency, results from mutations in the ATP-binding-cassette (ABC1) gene, which encodes cholesterol-efflux regulatory protein (CERP).

Purpose of the Study:

  • To investigate mutations in the ABC1 gene in patients with familial HDL deficiency.

Main Methods:

  • Studied three French-Canadian and one Dutch family with familial HDL deficiency.
  • Analyzed fibroblast cholesterol efflux and sequenced the ABC1 gene's coding region.
  • Used PCR and RFLP assays to track mutations within families and in controls.

Main Results:

  • Identified distinct ABC1 mutations in each family, leading to CERP truncation or altered amino acid residues.
  • All identified mutations segregated with low HDL-cholesterol levels.
  • No mutations were found in over 500 control chromosomes.

Conclusions:

  • ABC1 mutations are a primary cause of familial HDL deficiency linked to impaired cholesterol efflux.
  • CERP plays a critical role in HDL formation.
  • Modulating ABC1 offers a potential therapeutic approach to increase HDL concentrations.
Abstract

Related Concept Videos

ABC Transporters: Exporter01:31

ABC Transporters: Exporter

ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
ABC Transporters: Importer01:27

ABC Transporters: Importer

ATP-binding cassette or ABC transporters are a class of ATP-driven pumps that hydrolyze ATP to move solutes across the membrane. They can be grouped into importers and exporters. While exporters are present in all domains of life, importers exist only in bacteria and some plants.
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...